Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 05-03-2005, 03:41 PM   #1
Posts: n/a

MKC-1 is an orally-active, novel, small molecule, cell cycle inhibitor with a unique mechanism of action. Specifically, MKC-1 arrests cellular mitosis by inhibiting a novel intracellular target important in cellular trafficking that has been shown to be involved in cell division. In preclinical studies, MKC-1 demonstrated impressive activity in a broad range of tumor models. Clinical partial and durable responses have been observed in patients with previously treated NSCLC and metastatic breast cancers. Tested in over 250 patients to date, Miikana plans to initiate two phase II trials with MKC-1 for the treatment of breast cancer and non-small cell lung cancer.
  Reply With Quote
Old 05-03-2005, 08:43 PM   #2
al from canada
Posts: n/a
Thanks Rich,
If it is small molecule I'm surprised that they're not doing a brain mets study as well. That area really needs more work.
  Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump

All times are GMT -7. The time now is 04:39 AM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2021, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter